• Virax Biolabs filed a legal opinion supporting the issuance and sale of ordinary shares.
• Disclosure referenced an at-the-market offering agreement with a sales agent, dated Jan. 22, 2024.
• The filing incorporated the report into its registration statement and related prospectus supplements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-383683), on September 04, 2026, and is solely responsible for the information contained therein.